


# What is the role of S-ICD for ICD patients at high risk for infection?

## Patient Comorbidities and the risk of infection

~76% of ICD patients in the U.S. have  $\geq 1$  comorbidity associated with high risk for infection<sup>1-2</sup>




## Transvenous lead extractions due to infection<sup>5</sup>

In 2012, approximately 12,000 transvenous leads were extracted. Approximately 6,000 or 50% of the extractions were for infection.


Data shows that extraction for device infection is increasing over time while extraction for mechanical lead failure is decreasing.

Trends in Transvenous Lead Removal by Indication



## 1 year mortality rate of 12-31% following lead extraction<sup>6</sup>

A study from the Cleveland Clinic found that patients with transvenous device infections had a 12% mortality rate for a pocket infection at 1 year and a 31% mortality rate for an endovascular infection at 1 year.



## No Serious Bloodstream Infections

There were ZERO cases of serious bloodstream infections with S-ICD in the EFFORTLESS 3 year follow-up study.<sup>4</sup>

## AHA/ACC/HRS Guideline Recommended

S-ICD is Class I recommended for patients who are at high risk of infection or have inadequate vascular access and Class IIa recommended for any ICD patient if pacing is not required for bradycardia or VT termination or as part of CRT.

1. Polyzos, et al., Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace, 2015.
2. Friedman, et al., Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. JAMA Cardiol, 2016.
3. Al-Khatib, et al., 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death, Heart Rhythm 2017.
4. Boersma, et al., Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. J Am Coll Cardiol, 2017.
5. Deshmukh, et al., Trends in Use and Adverse Outcomes Associated with Transvenous Lead Removal in the United States. Circulation. 2015.
6. Tarakji KG, et al. Risk factors for 1-year mortality among patients with cardiac implantable electronic device infection undergoing transvenous lead extraction: the impact of the infection type and the presence of vegetation on survival. Europace. Apr 2014.

**CAUTION:** Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Instructions for Use" and MRI Technical Guide for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions.

**INDICATIONS FOR USE** The S-ICD System is intended to provide defibrillation therapy for the treatment of life-threatening ventricular tachyarrhythmias in patients who do not have symptomatic bradycardia, incessant ventricular tachycardia, or spontaneous, frequently recurring ventricular tachycardia that is reliably terminated with anti-tachycardia pacing.

**CONTRAINDICATIONS** Unipolar stimulation and impedance-based features are contraindicated for use with the S-ICD System.

**WARNINGS** • Concomitant use of the S-ICD System and implanted electro-mechanical devices (for example implantable neuromodulation/neurostimulation systems, ventricular assist device (VAD), or implantable insulin pump or drug pump) can result in interactions that could compromise the function of the S-ICD, the co-implanted device, or both. The S-ICD is intended as lifesaving therapy and should be seen as priority in the decision and evaluation of concomitant system implants over non-lifesaving applications. Electromagnetic (EMI) or therapy delivery from the co-implanted device can interfere with S-ICD sensing and/or rate assessment, resulting in inappropriate therapy or failure to deliver therapy when needed. In addition, a shock from the S-ICD pulse generator could damage the co-implanted device and/or compromise its functionality. Verify sensing configuration, operation modes, surgical considerations and existing placement of all involved devices prior to any co-implant. To help prevent undesirable interactions, test the S-ICD system when used in combination with the co-implanted device, and consider the potential effect of a shock on the co-implanted device. Induction testing is recommended to ensure appropriate detection and time to therapy for the S-ICD and appropriate post-shock operation of the co-implanted device. Failure to ensure appropriate detection and time to therapy delivery of the S-ICD system could result in patient injury or death. • Following completion of the interaction testing, thorough follow-up evaluation of all co-implanted devices should be performed to ensure that device functions have not been compromised. If operational settings of the co-implanted devices change or if patient conditions changes which may affect S-ICD sensing and therapy performance, re-evaluation of the co-implanted devices may be required. • All Boston Scientific S-ICD implantable components are designed for use with the Boston Scientific or Cameron Health S-ICD System only. Connection of any S-ICD System components to a non-compatible component has not been tested and could result in failure to deliver life-saving defibrillation therapy. • Always have external defibrillation equipment and medical personnel skilled in CPR available during implant and follow-up testing. If not terminated in a timely fashion, an induced ventricular tachyarrhythmia can result in the patient's death. • Using multiple pulse generators could cause pulse generator interaction, resulting in patient injury or a lack of therapy delivery. Test each system individually and in combination to help prevent undesirable interactions. Refer to "S-ICD System and Pacemaker Interaction" on page 73 for more information. • Attention is required to placement of the arm ipsilateral to the device implant to avoid injury of the ulnar nerve and brachial plexus while the patient is in the supine position during device implantation and before VF induction or shock delivery. The patient should be positioned with the arm abducted to an angle of no more than 60° with the hand in a supinated (palm up) position during the implant phase of the procedure. Securing the arm to an arm board is standard practice to maintain positioning of the arm during device implantation. Do not strap the arm too tightly during defibrillation testing. Elevation of the torso through use of a wedge may also add stress to the shoulder joint and should be avoided during defibrillation testing. • Use appropriate anchoring techniques as described in the implant procedure to prevent S-ICD System dislodgement and/or migration. Dislodgement and/or migration of the S-ICD System may result in an inappropriate shock or failure to deliver therapy to the patient. • Use caution when placing a magnet over the S-ICD pulse generator because it suspends arrhythmia detection and therapy response. Removing the magnet resumes arrhythmia detection and therapy response. • In patients with a deep implant placement (greater distance between the magnet and the pulse generator), magnet application may fail to elicit the magnet response. In this case the magnet cannot be used to inhibit therapy. • Advise patients to seek medical guidance before entering environments that could adversely affect the operation of the active implantable medical device, including areas protected by a warning notice that prevents entry by patients who have a pulse generator. • High shocking electrode impedance may reduce VT/VF conversion success. • When positioning the electrode and pulse generator, avoid excessive tension on the electrode, particularly if the electrode body extends over the pulse generator. This could cause structural damage, abrasion, and/or conductor discontinuity. • Although pliable, the electrode is not designed to tolerate excessive flexing, tight radius bending, kinking, or twisting. This could cause structural damage, conductor discontinuity, electrode migration, and/or dislodgement. • Electrode fracture, abrasion, under-insertion of the electrode connector into the pulse generator connector port, or a loose setscrew connection may result in compromised sensing, loss of therapy, or inappropriate therapy. • Following any sensing parameter adjustment or any modification of the subcutaneous electrode, always verify appropriate sensing. • Determine if the device and programmed parameters are appropriate for patients with SVTs because SVTs can initiate unwanted device therapy. • During a device software update, tachycardia therapy is suspended. Always monitor the patient and have external defibrillation equipment available during interrogation. • Do not expose a patient with an implanted S-ICD System to diathermy. • EMBLEM S-ICD devices are considered MR Conditional. Unless all MRI Conditions of Use are met, MRI scanning of the patient does not meet MR Conditional requirements for the implanted system. • The Programmer is MR Unsafe and must remain outside the MRI site Zone III (and higher) as defined by the American College of Radiology Guidance Document on MR Safe Practices. • During MRI Protection Mode the Tachycardia therapy is suspended. • MRI scanning after ERI status has been reached may lead to premature battery depletion, a shortened device replacement window, or sudden loss of therapy. • The Beeper may no longer be usable following an MRI scan. • The pulse generator may be more susceptible to low frequency electromagnetic interference at induced signals greater than 80 uV. • Immersion in saltwater and similar conductive fluid environments (i.e. ocean, saltwater pools) may divert some defibrillation shock energy away from the patient's heart into the surrounding conductive fluid (as evidenced by a lower-than-normal shock impedance). This may reduce VT/VF conversion success, especially in patients with low BMI.

**PRECAUTIONS** For specific information on precautions, refer to the following sections of the product labeling: clinical considerations, sterilization and storage, implantation, device programming, environmental and medical therapy hazards, hospital and medical environments, home and occupational environments, follow up testing, explant and disposal, supplemental precautionary information. • The S-ICD System has not been evaluated for pediatric use. • The S-ICD System does not provide long-term bradycardia pacing, cardiac resynchronization therapy (CRT), or antitachycardia pacing (ATP). • When implanting the S-ICD system in a patient with sternal wires, ensure that there is no contact between the sternal wires and the distal and proximal sense electrodes (for example, by using fluoroscopy). Compromised sensing can occur if metal-to-metal contact occurs between a sense electrode and a sternal wire. If necessary, re-tunnel the electrode to ensure sufficient separation between the sense electrodes and the sternal wires. • Implanting a replacement device in a subcutaneous pocket that previously housed a larger device may result in pocket air entrapment, migration, erosion, or insufficient grounding between the device and tissue. Irrigating the pocket with sterile saline solution decreases the possibility of pocket air entrapment and insufficient grounding. Suturing the device in place reduces the possibility of migration and erosion.

**Electromagnetic Interference (EMI) Precautions** • Avoid electromagnetic interference (EMI). Advise patients to avoid sources of EMI because EMI may cause the pulse generator to deliver inappropriate therapy or inhibit appropriate therapy. • Moving away from the source of the EMI or turning off the source usually allows the pulse generator to return to normal operation. • Examples of potential EMI sources are: Electrical power sources, Arc welding or resistance welding equipment (should remain at least 24 inches from the implant), Robotic jacks, High voltage power distribution lines, Electrical smelting furnaces, Large RF transmitters such as radar, Radio transmitters, including those used to control toys, Electronic surveillance (antitheft) devices, An alternator on a car that is running, Medical treatments and diagnostic tests in which an electrical current is passed through the body, such as TENS, electrocautery, electrolysis/thermolysis, electrodiagnostic testing, electromyography, or nerve conduction studies, Any externally applied device that uses an automatic lead detection alarm system (e.g., an EKG machine) • Home appliances. Home appliances that are in good working order and properly grounded do not usually produce enough EMI to interfere with pulse generator operation. There have been reports of pulse generator disturbances caused by electric hand tools or electric razors used directly over the pulse generator implant site. • Electronic Article Surveillance (EAS) and security systems. Advise patients how to avoid impact to cardiac device function due to antitheft and security gates, tag deactivators, or tag readers that include radio frequency identification (RFID) equipment. These systems may be found at the entrances and exits of stores, at checkout counters, in public libraries, and in point-of-entry access control systems. Patients should avoid lingering near or leaning against antitheft and security gates and tag readers. In addition, patients should avoid leaning against checkout counter-mounted and handheld tag deactivation systems. Antitheft gates, security gates, and entry control systems are unlikely to affect cardiac device function when patients walk through them at a normal pace. If the patient is near an electronic antitheft, security, or entry control system and experiences symptoms, they should promptly move away from nearby equipment and inform their doctor. • Cellular phones. Patients should not carry a cellular phone within 15 cm (6 inches) of the implanted device in order to avoid interaction which may cause the pulse generator to deliver inappropriate therapy or inhibit appropriate therapy. Advise patients to hold cellular phones to the ear opposite the side of the implanted device, and to avoid storing a cellular phone within 15 cm (6 inches) of the implanted device. Examples of storage locations to be avoided include a breast or other shirt pocket, on a belt, or in a handbag held near the implant location. • Static magnetic fields. Advise patients that extended exposure to strong (greater than 10 gauss or 1 mT) magnetic fields may suspend arrhythmia detection. Examples of permanent magnet-containing sources to be aware of include: Industrial motors if held within 60 cm (24 inches) of the pulse generator, MRI scanners, Large stereo speakers if held within 60 cm (24 inches) of the pulse generator, Telephone receivers if held within 1.27 cm (0.5 inches) of the pulse generator, Magnetic wands such as those used for airport security and in the Bingo game, Cellular phones, ear buds, or headphones, if held within 15 cm (6 inches) of the pulse generator, Magnetically attached charging port or cable, such as used in laptops or cellular phones, if held within 15 cm (6 inches) of the pulse generator, Be aware of other body-worn items which may contain magnets, such as wrist bands, jewelry, clothing, nametags, CPAP masks, etc.

**POTENTIAL ADVERSE EVENTS** Potential adverse events related to implantation of the S-ICD System may include, but are not limited to, the following: • Acceleration/induction of atrial or ventricular arrhythmia • Adverse reaction to induction testing • Allergic/adverse reaction to system or medication • Bleeding • Conductor fracture • Cyst formation • Death • Delayed therapy delivery • Discomfort or prolonged healing of incision • Electrode deformation and/or breakage • Electrode insulation failure • Erosion/extrusion • Failure to deliver therapy • Fever • Hematoma/seroma • Hemothorax • Improper electrode connection to the device • Inability to communicate with the device • Inability to defibrillate or pace • Inappropriate post-shock pacing • Inappropriate shock delivery • Infection • Injury to or pain in upper extremity, including clavicle, shoulder, and arm • Keloid formation • Migration or dislodgement • Muscle/nerve stimulation • Nerve damage • Organ injury or perforation • Pneumothorax • Post-shock/post-pace discomfort • Premature battery depletion • Random component failures • Stroke • Subcutaneous emphysema • Surgical revision or replacement of the system • Syncope • Tissue damage • Tissue redness, irritation, numbness or necrosis • Vessel injury or perforation

Transient procedural adverse events are expected in some patients. These include, but are not limited to, discomfort, pain and other systemic symptoms that might be related to medications or other interventions performed during implant. Patients who receive an S-ICD System may develop psychological disorders that include, but are not limited to, the following: • Depression/anxiety • Fear of device malfunction • Fear of shocks • Phantom shocks

92436235 B.4

**Boston Scientific**  
Advancing science for life™

**Cardiology**  
300 Boston Scientific Way  
Marlborough, MA 01752-1234  
[www.bostonscientific.com](http://www.bostonscientific.com)

Medical Professionals:  
1.800.CARDIAC (227.3422)  
Patients and Families:  
1.866.484.3268

© 2024 Boston Scientific Corporation or its affiliates. All rights reserved.

CRM-725507-AA